Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Nirmatrelvir is a protease inhibitor that stops the SARS-CoV-2 virus from replicating while ritonavir boosts the activity of ...

People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.

There is no proven treatment for long Covid-19, which can cause a range of debilitating symptoms in millions of Americans. Skip to content. Exclusive ...

Also Read: Pfizer's Paxlovid Demonstrates Safety But Raises Questions on Efficacy in Low-Risk Covid-19 Patients-NEJM Study The study involved patients aged 25 to 55 who were infected with SARS-CoV ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does ...

Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth in other drugs and product categories. The drugmaker posted a profit of ...

Biopharmaceutical company Pfizer will manufacture materials for the antiviral drug Paxlovid in Kalamazoo, Mich., after a $120 million investment for the treatment's first stateside factory.

Pfizer will provide up to 6 million courses of its antiviral COVID-19 treatment, Paxlovid, for the Global Fund, the pharmaceutical company said Sept. 22.

A recent patient-led case series highlights the potential benefits of extended courses of Pfizer Inc's (NYSE:PFE) Paxlovid (nirmatrelvir / ritonavir) for individuals with Long COVID. The study ...